According to FDA-approved labeling, headache is listed among the adverse reactions for both Ozempic (semaglutide for type 2 diabetes) and Wegovy (semaglutide for weight management)
DuhonRaymond James & AssociatesShreveportLouisiana$100K$354M$500K-65M$350K-5MRhonda LoyMorgan Stanley Wealth ManagementBaton RougeLouisiana$400K$397M$1.5-4M$750K-4.5MTerry GinnMerrill Wealth ManagementBaton RougeLouisiana$500K$333M$3.2-7.8M$2.2-4.1MJeff DraughonAmeriprise Financial ServicesAlexandriaLouisiana$0$1.2B$250-500K$500K-2MScott M
Clinical trials for Zepbound showed that participants achieved an average weight loss of 15% to 22.5%, depending on dosage, with results tracked over 72 weeks under controlled conditions
First, due to fewer relevant eligible studies, we did not limit the requirement for randomization
Subgroup analyses for continuous endpoints in relation to the secondary hypothetical estimand (on treatment with trial product) were performed using a mixed model with treatment by BMI group adjusted for the relevant continuous baseline variable, all nested within visit, and treatment by BMI groups was evaluated at week 52 using on-treatment data
Relationship to estradiol